deltatrials
Completed PHASE3 NCT00000517

Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)

Sponsor: Massachusetts General Hospital

Conditions Arrhythmia Atrial Fibrillation Cardiovascular Diseases Cerebral Embolism and Thrombosis Cerebrovascular Accident Cerebrovascular Disorders Heart Diseases Thrombophlebitis
Interventions warfarin
Updated 5 times since 2017 Last updated: Apr 9, 2014 Started: Jul 31, 1985 Primary completion: Jun 30, 1991 Completion: Jun 30, 1991

A PHASE3 clinical study on Arrhythmia and Atrial Fibrillation, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 5 data snapshots since 1985. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 1985

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.